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Abstract 
A new procedure for loading doxorubicin into large unilamellar vesicles (LUVs) is characterized. It is shown that 
doxorubicin can be loaded into LUVs composed of sphingomyelin/cholesterol (55:45 mole/mole) in response to a 
transmembrane MnSO4 gradient in the absence of a transmembrane pH gradient. Complex formation between doxorubicin 
and Mn 2+ is found to be a driving force for doxorubicin uptake. Uptake levels approaching 100% can be achieved up to a 
drug-to-lipid molar ratio of 0.5 utilizing an encapsulated MnSO4 concentration of 0.30 M. In vitro leakage assays how 
excellent retention properties over a 24 h period. The possible advantages ofa liposomal formulation of doxorubicin loaded 
in response to entrapped MnSO4 are discussed. © 1998 Elsevier Science B.V. All rights reserved. 
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I. Introduction 
Doxorubicin is a potent antineoplastic agent active 
against a wide range of human cancers. However, 
treatment with doxorubicin is associated with severe 
toxic side effects which include dose-limiting cardio- 
toxicity and myelosuppression [1-5]. When adminis- 
tered by intravenous injection, the use of liposomes 
to encapsulate doxorubicin can reduce toxic side ef- 
fects without decreasing drug potency [3,4,6-12]. 
Doxorubicin is an amphipathic weak base consist- 
ing of an anthraquinone moiety (the aglycone part) 
Abbreviations: 3H-CHE, 3H-cholesteryl hexadecyl ether; 
LUV, large unilamellar vesicle; ApH, pH gradient; pHo, extra- 
liposomal pH; pHi, intraliposomal pH 
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and an amine sugar. Previous work has shown that 
doxorubicin and other weak bases can be accumu- 
lated into vesicles with an acidic interior in response 
to the transmembrane pH gradient [13-15]. Recently, 
a new method for drug loading has been developed 
using LUVs containing Mn 2+ in the presence of the 
ionophore A23187 [35]. The ionophore A23187 
translocates one Mn 2+ ion to the outside of the 
LUV in exchange for the inward movement of two 
protons, thereby generating a pH gradient (interior 
acidic) across the bilayer, which drives drug uptake. 
Efficient loading of vincristine and ciprofloxacin has 
been demonstrated using this method. In the present 
study, the ionophore method was used to load doxo- 
rubicin. However, it was found that doxorubicin can 
be efficiently loaded into liposomes with a trans- 
membrane Mn 2+ gradient in the absence of iono- 
phore via the formation of intravesicular doxorubi- 
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cin-Mn 2+ complexes. It is shown that complex for- 
mation between doxorubicin and Mn 2+ provides a 
strong driving force for doxorubicin accumulation 
inside liposomes. 
2. Materials and methods 
2.1. Materials 
Egg sphingomyelin was purchased from Northern 
Lipids (Vancouver, BC). Cholesterol and the calcium 
ionophore A23187 were obtained from Sigma (Mis- 
sissauga, ON). Doxorubicin hydrochloride (adriamy- 
cin) was manufactured by Pharmacia nd Upjohn 
(Don Mills, ON). 14C-Mevalonic acid (RS-[2- 
14C]mevalonic acid, DBED salt) was purchased 
from Amersham Canada (Oakville, ON). 3H-Choles- 
teryl hexadecyl ether (3H-CHE) was produced by 
NEN Life Science Products (Boston, MA). 14C- 
Methylamine (14C-methylamine hydrochloride) was 
purchased from DuPont (Boston, MA). Sterile 
mouse serum was obtained from Cedarlane Labora- 
tories (Hornby, ON). Nucleopore polycarbonate fil- 
ters (25 mm, 0.1 ~tm pore size) were obtained from 
Costar Scientific (Toronto, ON). All chemicals were 
reagent grade. 
2.2. Preparation of 100 nm large unilamellar vesicles 
(LUVs) 
Liposomes were prepared by the freeze-thaw ex- 
trusion method as described previously by Hope et 
al. [16]. Throughout his study, 100 nm diameter 
large unilamellar vesicles consisting of sphingomye- 
lin/cholesterol (55:45 molar ratio) were used, because 
they have been shown to exhibit excellent retention 
properties [17]. Briefly, mixtures of sphingomyelin 
and cholesterol (55:45 mole ratio) were dissolved in 
2-methylpropan-2-ol at 60°C. A trace amount of 3H- 
CHE was added to achieve a final activity of 0.05 
gCi/gmole lipid, and the solution was then frozen in 
liquid nitrogen. This frozen material was lyophilized 
for at least 4 h under high vacuum to remove the 
organic solvent. Unless specified otherwise, the 
lyophilized lipid mixture was then hydrated at 50 
mM with a buffer containing 0.30 M MnSO4 and 
30 mM HEPES (pH 7.4) in a 60°C water bath. 
This suspension was subjected to five freeze-thaw 
cycles by alternating between liquid nitrogen and a 
60°C water bath with vigorous vortexing between 
cycles. Subsequently, the hydrated lipid mixture 
was extruded 10 times through two layers of poly- 
carbonate filters with pore size of 0.1 gm at 60°C 
using a water-jacketed extruder (Lipex Biomem- 
branes, Vancouver, BC). Phospholipid content of 
the LUVs (which accounts for 55% of the total 
lipid) was measured employing Fiske-Subbarow 
phosphate assay [18]. Subsequently, the specific 
activity of the liposomes (expressed as dpm/nmole 
total lipid) was determined by liquid scintillation 
counting. 
2.3. Doxorubicin uptake experiments" 
A transmembrane Mn 2+ gradient was generated 
across the LUVs by exchanging the extraliposomal 
buffer using Sephadex G-50 spin columns [15]. Sub- 
sequently, the lipid concentration was determined by 
liquid scintillation counting. Unless specified other- 
wise, all experiments involving the ionophore A23187 
used buffer containing 0.30 M sucrose, 20 mM 
HEPES and 15 mM EDTA at pH 7.4; experiments 
performed in the absence of the ionophore mployed 
buffer containing 0.30 M sucrose and 20 mM 
HEPES at pH 7.4. The transition temperatures of
sphingomyelins range from 40.5 to 57°C [19]; as a 
consequence, all uptake experiments were performed 
at 60°C in order to permit efficient partitioning of the 
drug into and across the lipid bilayer. A23187 was 
used at a concentration of 0.1 gg ionophore/~tmole 
lipid and LUVs were incubated with ionophore at 
60°C for 5 min prior to the addition of doxorubicin. 
The amount of doxorubicin used in each experiment 
varied depending on the desired drug-to-lipid ratio. 
After the addition of doxorubicin, the lipid concen- 
tration was 5 mM. Samples of this mixture were 
taken at specific time points, applied onto spin col- 
umns and centrifuged at 760 × g for 2 min. This step 
removes unencapsulated doxorubicin, leaving lipo- 
somes with encapsulated doxorubicin in the eluant. 
In order to determine the drug-to-lipid ratio, part of 
the eluant was subjected to liquid scintillation count- 
ing to assay for the amount of lipid, while another 
part was added to a solution of 1.0% Triton X-100, 
2.0 mM EDTA and 20 mM HEPES (pH 7.5) for the 
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quantification of doxorubicin by absorption spectro- 
scopy at 480 nm (e= 1.06× 104 M -1 cm -1 [20]). The 
total drug-to-lipid ratio (100% value) in the uptake 
mix was determined at specific time points by the 
same procedure but omitting the spin column centri- 
fugation step. 
2.4. Determination of  pH gradients 
To determine the pH gradient (inside acidic) 
present across the lipid bilayer, a trace amount of 
14C-methylamine [21] was added to the uptake cock- 
tail (final activity = 0.2 ~tCi/ml). The doxorubicin up- 
take experiments were performed as described above, 
except dual 3H- and 14C-radioisotope liquid scintilla- 
tion counting was used. Assuming a trapped vol- 
ume of 1.5 ~tl per ~tmole lipid for 100 nm diameter 
LUVs [16,22], intraliposomal and extraliposomal 
methylamine concentrations could be determined. 
The pH gradient (ApH) can then be calculated by 
[21,23]: 
ApH = log {[H+]inside/[H+]outside} = 
clog { [methylamine]insi,te/ [methylamine]outside ) 
For the determination of ApH in LUVs with a 
basic interior, 14C-mevalonic acid was used instead 
of 14C-methylamine [23]. 
2.5. Absorption spectra 
The effect of Mn 2+ on the doxorubicin absorption 
spectrum was determined by mixing various concen- 
trations of MnSO4 with doxorubicin (54 ~tM final 
concentration) in 100 mM HEPES (pH 7.4). Absorp- 
tion spectra from 350 to 700 nm were taken using a 
Shimadzu UV160U spectrophotometer. At saturat- 
ing concentration of Mn 2+, the pH dependence of 
the doxorubicin-Mn 2+ complex was studied. 400 
mM MnSO4, 24 laM doxorubicin and 100 mM of 
various buffers were used: MES as the buffer for 
pH 5.2 and 5.6, PIPES buffer for pH 6.0, 6.4 and 
6.8 and HEPES was used at pH 7.2, 7.5, 7.8 and 8.0. 
Spectra of doxorubicin loaded in the presence or 
absence of A23187 were compared with the spectrum 
of unencapsulated doxorubicin in the presence of 
empty liposomes. 
2.6. In vitro leakage assay 
Doxorubicin was loaded at a drug-to-lipid ratio of 
0.5 (mole/mole) in the presence or absence of 
A23187. Each uptake mixture was incubated for 70 
min at 60°C after which it was applied onto spin 
columns to remove unencapsulated doxorubicin. 
After centrifugation, an equal volume of sterile 
mouse serum was added followed by incubation at 
37°C for up to 24 h. The final concentration of lip- 
osomes was 1 mM. Aliquots were taken out at speci- 
fied time points for the determination f doxorubicin 
retention. 
3. Results 
3.1. Doxorubicin is accumulated into Mn 2 + containing 
L UVs in the absence of a pH gradient 
Previous studies [35] have shown that amino-con- 
taining drugs such as vincristine and ciprofloxacin 
can be loaded into liposomes exhibiting a Mn 2+ gra- 
dient in the presence of external EDTA and the ion- 
ophore A23187. This method was also found to load 
doxorubicin efficiently. The kinetics of doxorubicin 
loading into 100 nm diameter LUVs at 60°C is 
shown in Fig. 1A. The transbilayer pH gradient 
was also measured, emonstrating an initial pH gra- 
dient of 3.4 units (inside acidic). Upon drug addition, 
this gradient was quenched within 5 min. However, 
the ApH was later re-established, rising to 2.4 units 
at t=90 min. The magnitude of the re-established 
ApH varied depending on the drug-to-lipid ratio 
used in the experiment (Fig. 1B). 
The disappearance and subsequent recovery of the 
acidic gradient was accompanied by marked color 
changes: the solution was initially red in color 
(t= 0) and then turned purple within 5 min. After 
45 min, the color changed back to red. The transient 
purple color could not be due to the change of the 
internal pH, since doxorubicin turns purple only at 
pH values higher than 8 (results not shown). The 
14C-mevalonic acid data show that no basic pH gra- 
dient was generated throughout the entire uptake 
process (Fig. 1A). This means that the highest intra- 
liposomal pH at any point during drug uptake was 
equivalent to the extraliposomal pH (i.e. pH 7.4). 
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Interestingly, doxorubicin uptake continued be- 
tween 5 and 30 min despite the absence of any acidic 
gradient (Fig. 1A). This suggested that the pH gra- 
Fig. 1. (A) Time course of doxorubicin uptake in the presence 
of A23187 (o) into LUVs containing MnSO4 (0.30 M). The 
acidic (O) or basic ([]) nature of the LUV interior was deter- 
mined during the uptake process using ~4C-methylamine and 
laC-mevalonic acid as ApH probes, respectively. The color of 
the uptake mixture is indicated on top of the diagram. Uptake 
was performed at a drug-to-lipid molar ratio of 0.53 with an 
A23187 concentration f 0.1 Ixg/Ixmole lipid. (B) Final pH gra- 
dient (interior acidic) re-established after loading at various 
drug-to-lipid ratios in the presence of A23187. Final pH gra- 
dients were determined using laC-methylamine after an equili- 
brium interior pH had been established. (C) Time course of 
doxorubicin uptake in the absence of A23187 (n). The pH of 
the LUV interior was monitored using laC-methylamine (O) 
and 14C-mevalonic a id (D). The color of the uptake mixture is 
indicated on top of the diagram. Uptake was performed at a 
drug-to-lipid ratio of 0.45. 
dient was not required for doxorubicin uptake. To 
test this hypothesis, uptake of doxorubicin was ex- 
amined in the absence of the ionophore A23187. The 
kinetics of doxorubicin uptake in the absence of 
A23187 (Fig. 1C) are very similar to those in the 
presence of A23187 (Fig. 1A). Only background lev- 
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Fig. 2. Equilibrium doxorubicin uptake into LUVs containing 
MnSO4 in the presence (0) or absence (w) of A23187 at various 
drug-to-lipid ratios. All uptake experiments were performed at 
60°C and were continued until the uptake levels became con- 
stant (60-120 min). LUVs used for both systems were com- 
posed of sphingomyelin/cholesterol (55:45 molar ratio) and con- 
tained 0.30 M MnSO4 titrated to pH 7.4 by 30 mM HEPES. 
B. C.L, Cheung et al. / Biochimica et Biophysica Acta 1414 (1998,) 205-216 209 
0.8  - -  
0.6 
~= 0.4 
02 
O0 
2+ 500 mM - -  OmM Mn 
(purple) A A - -  2mM 0.35 
IA  ~ - -  - lOmM 
I 1 % 1 A  O.3O 
- ~ /#{::~i~L/~ ~. , -  :l..,,, ~ - - - -  50raM 
/~ ~,:~:~'~ ./\/ ...... 100rnM 0.25 
//./:] ~" \'~.";i/ - - ' -  200raM O 
/ / / . ' J ' t~? : : ) l  -- '" 400mM ~ 0.20 
U Y  ~'~£~' ! i t  500mM ~ 0"15 
~..  0.10 
o o°°  
I I I l I I I 
350 400 450 500 550 600 650 700 
Wavelength (nm) 
-C  
t F I I I I 
5.0 5.5 6.0 6.5 7.0 7.5 8.0 
pH 
0 .40  - 
0.35  - 
0.30  - 
0.25 - 
e- 0.20 -o= 
o 0.15 - 
< O.lO -
0 .05  - 
0 .00  
B pH 8 .0  (purple) 
'/{ :z: 
I I I I 
350 400 450 500 550 600 650 700 
- -  pH 5 .2  
- -  pH 5.6 
- -  - pH 6 .0  
- - - -  pH 6 .4  
...... pH 6.8  
- - - -  pH 7.2 
---- pH 7.5 
- -  pH 7 .8  
it °"'° 
I I 
Wavelength (rim) 
4 
<I 
0 
i/i ¢-1 
< 
0.55 
0.50 
0.45 
0.40 
0.35 
0.30 
0.25 
0.20 
0.15 
0.10 
0.05 
0.00 
_D f~' .  
V'\ 
t l  \ 
..... I ~". 
\',, 
\'.,.. ~ , . .  
i i i i "T" - -T - ' - I  
350 400 450 500 550 600 650 700 
Wavelength (nm) 
Fig. 3. (A) Absorption spectra of doxorubicin in the presence of various concentrations of MnSO4. Doxorubicin (54 gM) was mixed 
with 0, 2, 10, 50, 100, 200, 400 or 500 mM MnSO4. All solutions were buffered at pH 7.4 by 100 mM HEPES. The color of the up- 
take mixture is indicated in parentheses. (B) Absorption spectra of doxorubicin-Mn 2+complexes at various pH values. MnSO4 (400 
mM) and doxorubicin (24 p,M) were buffered using 100 mM concentrations of the following buffers: MES pH 5.2-5.6; PIPES pH 
6.0-6.8 and HEPES pH 7.2-8.0. The color of the uptake mixture is indicated in parentheses. (C) Plot of absorbance (A580) vs. pH. 
The pKa of the doxorubicin-Mn 2+complex was determined from the inflection point of the curve (pKa = 6.6). (D) Absorption spectra 
of unencapsulated doxorubicin i  the presence of empty liposomes (--), and of encapsulated doxorubicin, loaded either in the presence 
of A23187 (...) or the absence of A23187 (- • -). All spectra were obtained at a drug-to-lipid molar ratio of 0.5. 
els of methylamine or mevalonic acid were found 
entrapped inside liposomes during uptake in the ab- 
sence of A23187, indicating that no pH gradient was 
generated uring the uptake process. The intralipo- 
somal and the extraliposomal pH values were stable 
at pH 7.4 throughout the uptake process. The solu- 
tion turned from red to purple within 5 min after 
uptake had begun and it stayed purple thereafter. 
Doxorubicin was loaded at various drug-to-lipid 
ratios in the presence or absence of A23187 (Fig. 
2). Both systems demonstrated similar doxorubicin 
loading efficiencies. Nearly 100% drug uptake could 
be achieved up to a drug-to-lipid ratio of approx. 
0.5. At higher drug-to-lipid ratios, the efficiency of 
drug uptake decreased. A drug-to-lipid ratio of ap- 
prox. 1 was therefore used in experiments designed to 
detect possible differences in uptake levels between 
different systems. 
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Fig. 4. Effects of extraliposomal pH on doxorubicin uptake in 
the presence (e) or in the absence of A23187 (111). All uptake 
experiments employed 0.30 M MnSO4+30 mM HEPES (pH 
7.4) containing liposomes and doxorubicin was loaded at a 
drug-to-lipid ratio of 1.1. In the extraliposomal buffers, HEPES 
was used to buffer at pH 7.0, 7.4 and 8.0 while HEPES and 
PIPES were used to buffer at pH 6.0 and 6.5. 
3.2. Doxorubicin forms complexes with entrapped 
Mn 2 + ions 
In order to explore the mechanism of doxorubicin 
uptake into liposomes exhibiting a transmembrane 
Mn 2+ gradient but no pH gradient, the formation 
of doxorubicin-Mn 2+complexes was investigated us- 
ing absorption spectroscopy. Absorption spectra of 
doxorubicin at pH 7.4 in the presence of various 
concentrations of MnSO4 are shown in Fig. 3A. A 
gradual red shift was observed in the spectra upon 
the addition of Mn 2+, and the color of the solution 
turned from red to purple at higher Mn 2+ concen- 
trations. Doxorubicin (54 ~tM) was found to be sa- 
turated with Mn 2+ at approx. 400 mM MnSO4. Fig. 
3B shows the change in absorption spectra of the 
doxorubicin-Mn 2+complex (at the saturating con- 
centration of Mn 2+) when titrated from pH 5.2 to 
8.0. At pH 5.2, most of the complex is dissociated, 
resulting in an absorption spectrum resembling the 
characteristic absorption peak for free doxorubicin 
that has a peak at approx. 480 nm. Between pH 
6.0 and 7.8 the spectrum was red-shifted, resulting 
in a spectrum characteristic of the doxorubicin- 
Mn 2+ complex. A further increase in pH beyond 
8.0 caused precipitation of Mn(OH)2. The absorb- 
ance of the doxorubicin-Mn 2+ complex varies signifi- 
cantly between pH 5.2 and 8.0, with the most drastic 
changes at 580 nm. When plotting the change in A580 
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Fig. 5. (A) Effect of the intraliposomal MnSO4 concentration 
on doxorubicin uptake achieved in the absence of A23187. (B) 
The effect of intraliposomal MnSO4 concentration on doxorubi- 
cin uptake (e) and on the final acidic gradient (©) in the pres- 
ence of A23187. Doxorubicin uptake and the final acidic gra- 
dient were determined after their readings became constant (60- 
120 min). All concentrations of MnSO4 solutions were titrated 
to and buffered at pH 7.4 with 30 mM HEPES. When no 
MnSO4 was present, the LUVs contained 0.30 M Na2SO4 and 
30 mM HEPES (pH 7.4). Uptake in both panels was performed 
at a drug-to-lipid ratio of 1.0 at 60°C. 
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versus the pH, the apparent pKa of complex forma- 
tion was determined to be approx. 6.6 (Fig. 3C). 
The characterization f the liposomal doxorubicin 
loaded in the presence or absence of A23187 was also 
performed using absorption spectroscopy. Absorp- 
tion spectra were taken after doxorubicin had been 
loaded into liposomes (Fig. 3D). As a control, a 
spectrum of free doxorubicin in the presence of 
empty liposomes was taken. All spectra were ob- 
tained from doxorubicin and liposomes at a drug- 
to-lipid ratio of approx. 0.5. In the absence of 
A23187, the (loaded) doxorubicin spectrum shifted 
to higher wavelengths resembling a non-saturating 
doxorubicin-Mn 2+ complex spectrum at pH 7.4. In 
the A23187 containing system, the spectrum of lip- 
osomal doxorubicin was identical to that of the un- 
encapsulated doxorubicin, indicating that the doxo- 
rubicin was not complexed to Mn 2+. 
3.3. Effects of external pH and entrapped Mn 2 + levels 
on complex dependent doxorubicin accumulation 
To investigate the influence of the external pH on 
doxorubicin uptake, the extraliposomal pH (pHo) in 
uptake experiments was varied while keeping the in- 
traliposomal pH (pHi) constant at pH 7.4. Fig. 4 
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Fig. 7. In vitro leakage assay of liposomal doxorubicin using 
50% mouse serum. Liposomal doxorubicin was loaded at a 
drug-to-lipid ratio of 0.5 in the presence (1) or in the absence 
(I) of A23187 by incubating doxorubicin with liposomes at 
60°C for 70 min. Subsequently, the liposomal doxorubicin was 
centrifuged through spin columns before incubating for 24 h 
with mouse serum at 37°C. The lipid concentration i the mix- 
ture containing 50°/,, mouse serum during the leakage assay was 
1 mM. 
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Fig. 6. Effect of pH of the encapsulated MnSO4 on doxorubicin 
uptake in the absence of A23187. Encapsulated MnSO4 solu- 
tions were either untitrated (pH 4.0, dashed bars), or titrated 
with 30 mM HEPES (pH 7.4, open bars). The drug-to-lipid ra- 
tios administered were 0.49 and 1.36. 
shows the effect of the pHo on the loading of dox- 
orubicin into Mn2+-containing liposomes in the ab- 
sence of A23187 using a drug-to-lipid ratio of 1.1. 
Doxorubicin uptake remained constant from pH 6.0 
to 6.5 and gradually increased as the pHo rose from 
pH 6.5 to 8.0. By measuring the pH gradients during 
these uptake processes, it was found that the pHi 
became equal to the pHo as soon as drug uptake 
had begun (data not shown), regardless of the initial 
pH gradient. 
The effect of the Mn 2÷ concentration e capsulated 
inside the liposomes on the level of doxorubicin up- 
take was investigated both in the presence and ab- 
sence of A23187. Liposomes with no Mn 2÷ (employ- 
ing 0.30 M Na2SOn-containing liposomes), 0.15 M, 
0.30 M, 0.45 M and 0.60 M MnSO4 (buffered at pH 
7.4 with 30 mM HEPES) were used in the uptake 
experiments. The results in Fig. 5A show that 0.30 M 
Mn 2÷ was sufficient o achieve a high level of drug 
uptake at a drug-to-lipid ratio of 0.96 in the absence 
of ionophore. A sharp increase in drug uptake was 
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observed between 0 M and 0.15 M Mn 2+ and a fur- 
ther but moderate increase was found between 0.15 
M and 0.30 M. The level of drug uptake then leveled 
off at 85% at Mn 2+ concentrations higher than 0.30 
M. At a drug-to-lipid ratio of 1.0, doxorubicin up- 
take in the presence of A23187 showed very similar 
results (Fig. 5B). 
The reason we employed entrapped MnSO4 at pH 
7.4 was to eliminate any effects of an initial pH gra- 
dient on doxorubicin uptake in the Mn 2+ containing 
system, thus simplifying data interpretation. To test 
whether liposomes with unbuffered MnSO4 (pH 4.0) 
could be used for doxorubicin loading instead of the 
titrated MnSO4 solution at pH 7.4, doxorubicin up- 
take into liposomes containing MnSO4 encapsulated 
at pH 4.0 or at pH 7.4 were performed and the 
results are illustrated in Fig. 6. Fig. 6 (left) (in the 
presence of A23187) and Fig. 6 (right) (in the ab- 
sence of A23187) show no significant difference in 
drug loading effectiveness between the pH 4.0 and 
the pH 7.4 MnSO4-entrapped liposomes. 
3.4. Doxorubicin is stably entrapped after 
accumulation i  response to a Mn 2+ gradient 
To assess the stability of the liposomal doxorubi- 
cin systems, in vitro leakage assays were performed 
employing 50% (v/v) mouse serum. Doxorubicin was 
loaded in the presence or absence of A23187 at a 
drug-to-lipid ratio of 0.5. After removing unencapsu- 
lated doxorubicin (and A23187: see [35]), the lipo- 
somes loaded with doxorubicin were diluted with 
mouse serum and incubated at 37°C for 24 h. The 
final lipid concentration i 50% mouse serum was 
1 raM. Fig. 7 shows that virtually no drug leakage 
was observed over a 24 h period for LUVs loaded in 
the presence and absence of A23187. 
4. Discussion 
The results presented here demonstrate a novel 
method for the loading of doxorubicin into lipo- 
somes. It is shown that doxorubicin uptake can be 
driven by a transmembrane Mn 2+ gradient, in the 
absence of any pH gradient. Loading procedures 
for doxorubicin described previously all rely on the 
presence of a transmembrane pH gradient o drive 
uptake [24]. Loading of doxorubicin in response to a 
transmembrane Mn 2+ gradient relies on the forma- 
tion of a membrane-impermeable complex with 
Mn 2--. In the following section, we discuss the mech- 
anism and properties of this loading process and po- 
tential applications. 
The formation of doxorubicin-Mn 2+ complexes, 
with a high stability constant (pKd = 7.0) has been 
previously described [25]. Complex formation is ac- 
companied by the changes in the absorption spec- 
trum of doxorubicin upon titrating with Mn 2+ (Fig. 
3A), which changes the color of doxorubicin from 
red to purple. This color change is also observed 
during doxorubicin loading into the liposomes in re- 
sponse to a Mn 2÷ gradient in both the presence and 
absence of A23187. In the presence of the ionophore 
A23187, however the color changes back to red after 
the doxorubicin is loaded, indicating dissociation of 
A NH2 OH 
I~,~CH 3 
HOH2C--C 
II o o 
0 
N , . . ' "  
Mn 2+ 
o 
o 9 I ~ C CH2OH 
'"OH 
H3CO O OH O 
f i<./ 
HO NH2 
Fig. 8. (A) Chemical structure of the doxorubicin-Mn 2+ (2:1) 
complex. (B) Schematic representation f reactions involved in 
the loading of doxorubicin in response to a transmembrane gra- 
dient Mn 2+. Hydroxyl (-OH) groups attached to the doxorubi- 
cin molecule are on the anthraquinone moiety of doxorubicin; 
amine (-NH2 or -NH~-) group attached to the doxorubicin mol- 
ecule corresponds to the amine on the sugar moiety. 
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Fig. 8. (continued) 
the doxorubicin-Mn 2+ complex after re-establish- 
ment of the pH gradient (inside acidic) by the ion- 
ophore. This was confirmed by the absorption spec- 
trum of the liposomal doxorubicin that was loaded 
in the presence of A23187 (Fig. 3D), which is char- 
acteristic of free (i.e. not complexed to Mn 2+) 
doxorubicin. The absorption spectrum of liposomal 
doxorubicin loaded in the absence of ionophore is 
red-shifted, indicating the formation of complexes 
with Mn 2+. 
It has been reported that doxorubicin molecules 
complex with Cu 2+ ions in a 1:1 or 2:1 ratio at 
pH 7.4, or as a polymeric complex [26], and one 
proton is released from the aglycone portion of 
each doxorubicin molecule upon complexation. As- 
suming that similar behavior is observed for Mn 2+, a 
model for doxorubicin complexation with Mn 2+ is 
given in Fig. 8A (for the 2:1 complex). Upon loading 
into liposomes, complexation of two doxorubicin 
molecules with one Mn 2+ ion will release two pro- 
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tons, thereby acidifying the intraliposomal medium. 
This will result in the protonation of the next two 
doxorubicin molecules that enter the liposome inte- 
rior. The overall doxorubicin uptake scheme is out- 
lined in Fig. 8B. A consequence of this loading 
scheme is that the pHi will equilibrate to the pHo, 
as was found in experiments where the external pH 
was varied (data not shown). As long as pHi < pHo, 
doxorubicin that enters the liposome interior will be 
protonated; protonation of doxorubicin depletes the 
intraliposomal protons and raises the pHi. Protona- 
tion is the force for driving doxorubicin uptake until 
pHi = pHo. After that, uptake will take place by al- 
ternating between Mn 2+ complexation and protona- 
tion as given in Fig. 8B. In the opposite case, when 
pHi > pHo initially, doxorubicin that enters the lip- 
osome interior will complex with Mn 2+. This will 
result in the release of a proton from the aglycone 
region, which decreases the pHi until pHi =pHo. 
Subsequently, uptake again will take place by alter- 
nating between complexation and protonation. In 
the experiments described in Fig. 4, the pHi was 
rapidly equalized to the pHo within the first 5 min 
of drug loading. Only background levels of doxoru- 
bicin uptake were observed at pH 6.5 or lower, and 
drug uptake increases at higher pH (Fig. 4). This can 
be explained by the fact that doxorubicin-Mn 2+ com- 
plexation is pH dependent [25] (Fig. 3B,C). Half of 
the maximum level of doxorubicin uptake occurs at 
about pH 7.0, close to the pKa of doxorubicin-Mn 2+
complex formation (pKa = 6.6; Fig. 3C). 
Under the appropriate xperimental conditions, 
doxorubicin loading in response to a transmembrane 
Mn 2+ gradient is very efficient. Uptake levels of 
100% can be reached up to a drug-to-lipid ratio of 
0.5 (Fig. 2). When starting with a higher drug-to- 
lipid ratio (1.1), doxorubicin can even be loaded up 
to a final drug-to-lipid ratio of 0.8 (73% uptake). 
Overall, the efficiency of the loading procedure is 
comparable to that achieved employing the pH gra- 
dient loading of doxorubicin [27]. 
Although also for ciprofloxacin complex formation 
with divalent metal ions has been described [28] there 
was little uptake of this drug in response to a Mn 2+ 
gradient [35]. The low levels of uptake in the absence 
of ionophore could be explained by the small pH 
gradient present, since unbuffered MnSO4 solutions 
with a pH of 3~, were used in those experiments. 
Apparently, metal ion-ciprofloxacin complex forma- 
tion does not lead to drug uptake. This might be due 
to a less stable complex, a different pH optimum for 
complex formation, and/or membrane permeability 
of the complex. 
Complexation of doxorubicin with several metal 
ions (such as Fe 3+ and Cu 2+) has been reported to 
facilitate the binding of the anthracycline to DNA, 
promote the peroxidation of lipids and enhance the 
generation of reactive oxygen species [25,29-32]. 
These actions inside cells promote cell death through 
damaging intracellular organelles. For doxorubicin- 
Fe 3+ and doxorubicin-Cu 2+complexes, enhanced cy- 
totoxicity has been described [26,30,32-34]. There- 
fore, a liposomal formulation of doxorubicin-Mn 2+ 
could be therapeutically advantageous. In this re- 
gard, a concentration of MnSO4 (0.30 M) iso-os- 
motic to physiological saline solution was employed 
and was found to be sufficient o drive a high level of 
doxorubicin uptake at drug-to-lipid ratios as high as 
1.0. Finally, in vitro leakage assays reveal that dox- 
orubicin loaded in response to entrapped Mn 2+ ex- 
hibits excellent retention over a 24 h incubation pe- 
riod at 37°C. These properties suggested that 
liposomal doxorubicin formulations loaded in re- 
sponse to entrapped MnSO4 might have promise 
for in vivo applications. 
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